The State Duma is considering the bill No. 818556-8 “On Amendments to Part Four of the Civil Code of the Russian Federation” (the “Bill”), the authors of which propose to amend the procedure for making decisions on the use of inventions, utility models and industrial designs (“Objects of patent rights”) established by Article 1360 of the Civil Code of the Russian Federation.

The new review of the most notable patents disputes in Life Sciences in Russian and the CIS.

• pdf, 2.52 Mb

On 5 December 2024 the results of the annual Pravo-300 law firms’ ranking were announced at an awarding ceremony at The Carlton Hotel in Moscow. This year Lidings expertise is highly praised in 17 key practice areas.

Lidings’ Intellectual Property practice team succeeded in obtaining cancellation of registration of a drug in a dispute against the holder of the marketing authorisation (MA) due to the fact that during the process of registration of a generic drug product the Ministry of Health of Russia received false information from the holder of the MA.

Senior Associate in the Lidings’ Intellectual Property practice Vladislav Ryabov will take part in an annual conference entitled Intellectual Property - 2024 organized by Pravo.ru. The conference will take place on 22 November in Hotel Baltschug Kempinski.

Senior associate of the Lidings’ Intellectual Property practice Vladislav Ryabov will take part in the International Conference entitled Intellectual Property Right: Challenges of 21st Century. The conference will take place on 14-16 November 2024 at the campus of the National Research Tomsk State University.

On November 7, 2024, Lidings held a round table discussion " Launch of Medicines and Pharmaceutical Substances in Russian and Indian Markets" as part of the business program of the Forum "Under One Sun: Russia-India. Business and Culture ", which took place in Delhi, November 6 - 8, 2024.

Highlights of the event in our overview.

Despite the fact that the issue of intellectual property rights turnover is included in the perimeter of antimonopoly regulation, until recently the Russian Antitrust Agency took rather an observant position.

The regulator's position was that the issue of patent infringement is a private legal dispute between original and generic manufacturers, which should not affect the turnover of drugs, particularly the execution of contracts based on the results of public procurement. Only in isolated cases the Russian Antitrust Agency has established the fact of patent infringement and issued a corresponding order on the inadmissibility of anti-competitive practices.

Now the reverse trend has clearly emerged.

More in our update.

On 27.09.2024 the Decree of the Government the Russian Federation No. 1278 was published. This Decree amends for the Regulation on Patent and Other Fees for Legally Significant Actions.

On July 22, 2024, the President of Russia signed Federal Law No. 190-FZ “On Amendments to Part Four of the Civil Code of the Russian Federation” (Federal Law). The amendments establish the procedure for the use of works whose author or right holder is unknown (“orphan” works).